Manipal Health opens Rs 8,000 crore IPO at Rs 560-590 band

The Development

Manipal Health Enterprises Limited opened its initial public offering for subscription on Wednesday, 29 July 2026, with bidding scheduled to close on Friday, 31 July 2026, according to the red herring prospectus (RHP) filed with the Securities and Exchange Board of India (SEBI). The offer combines a fresh issue of equity shares aggregating up to Rs 8,000 crore with an offer for sale of up to 2,16,13,834 shares by seven selling shareholders. At the price band of Rs 560 to Rs 590 per share, the total offer is valued at about Rs 9,275 crore, per the issue records, making it one of the largest mainboard issues of the year.

Anchor bidding took place on Tuesday, 28 July 2026, per the RHP timetable, ahead of the public window. As of the close of the second day of bidding on 30 July, the issue had been subscribed about 0.45 times overall per exchange bid data, with the qualified institutional buyer portion at 0.60 times, the retail portion at 0.45 times and the non-institutional portion at 0.14 times. The shares are proposed to be listed on the BSE and the NSE, with the NSE as the designated stock exchange. The development was surfaced through coverage on the IPO desks of Mint and The Economic Times.

The Company

Manipal Health Enterprises operates a pan-India network of multispecialty hospitals. The company discloses that, as of 31 March 2026, it ran 49 hospitals (including six operated-and-managed facilities) with 13,037 licensed beds across 14 states and union territories, and that it served 7.63 million patients in Fiscal 2026. It describes itself, citing a CRISIL report in the RHP, as the largest pan-India multispecialty hospital network by bed capacity, with a clinical focus on cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and renal sciences, which it groups as "CONGO-R". The company discloses a workforce of 24,240 employees.

Per the RHP's restated consolidated financials, revenue from operations was Rs 10,335.75 crore in Fiscal 2026, up from Rs 8,242.25 crore in Fiscal 2025 and Rs 6,171.63 crore in Fiscal 2024. Profit for the year was Rs 916.52 crore in Fiscal 2026, against Rs 1,081.67 crore in Fiscal 2025 and Rs 533.20 crore in Fiscal 2024, so profit declined even as revenue rose. The company discloses total borrowings of Rs 10,553.43 crore as of 31 March 2026, up from Rs 4,766.83 crore a year earlier. The promoters include Dr Ranjan Ramdas Pai together with the Manipal and MEMG group entities.

The Offer Structure

The offer is a mix of a fresh issue and an offer for sale. The fresh issue aggregates up to Rs 8,000 crore, while the offer for sale covers up to 2,16,13,834 shares by seven shareholders, among them Imperius Healthcare Investments (up to 1,08,08,861 shares), Manipal Education and Medical Group India (up to 67,92,002 shares) and TPG SG Magazine. The company discloses it will not receive any proceeds from the offer for sale. The price band is Rs 560 to Rs 590 per share and the lot size is 25 shares, so the minimum application at the upper end of the band works out to Rs 14,750 for a retail bidder, per the issue terms.

Per the RHP, the objects of the fresh issue are the repayment or prepayment of certain borrowings of its material subsidiary Manipal Hospitals Private Limited (about Rs 5,552.76 crore), the acquisition of a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (about Rs 574 crore), and general corporate purposes. The book-running lead managers are Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India and DBS Bank India, with KFin Technologies as registrar. Readers working through the arithmetic of an allotment can use Oquilia's lumpsum calculator or CAGR calculator, and prior coverage sits on the /news desk.

Risk Factors

The RHP sets out a detailed risk-factors section, of which the following are among the most material. The company discloses geographic concentration: it derived 46.40% of revenue from operations in Fiscal 2026 from its hospitals in Karnataka, and states that disruption there could have a material adverse effect on its business. Among the risks the company discloses is specialty concentration, with 64.30% of gross inpatient revenue in Fiscal 2026 coming from the CONGO-R specialties.

The RHP also lists a related-party dimension to the use of proceeds: part of the net proceeds is proposed for the prepayment of non-convertible debentures issued by a subsidiary to DBS Bank Ltd, the parent of book-running lead manager DBS Bank India, which is deemed an associate of one of the promoters. The company further discloses that 49.68% of gross inpatient revenue in Fiscal 2026 came from insurance and third-party administrators, and that the offer is being made under Regulation 6(2) of the SEBI ICDR Regulations because its net tangible assets were below the threshold under the standard eligibility route in Fiscal 2026. These are risks the company itself was required to disclose, not an assessment by this desk.

What Happens Next

Per the RHP, the bidding window closes on 31 July 2026, with the UPI mandate confirmation cut-off at 5:00 p.m. on the closing day. From there the standard mainboard mechanics follow: the basis of allotment is expected to be finalised on or around 3 August 2026, after which the unblocking of application amounts for unsuccessful and partially successful bidders and the crediting of shares to successful applicants take place.

The shares are then scheduled to list on the BSE and the NSE, with a tentative listing date of 5 August 2026 per the issue schedule. Each of these steps is a process defined by the offer document and exchange notices; the actual subscription level at close, the basis of allotment and the listing price will be confirmed by the exchanges as they occur.

FAQ

Should I apply for this IPO?

Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges; read it directly before making any decision.

What is the price band and lot size?

Per the issue terms, the price band is Rs 560 to Rs 590 per share and the lot size is 25 shares. At the upper end of the band, a single lot works out to Rs 14,750, which is the minimum application amount for a retail bidder. Applications are made through the UPI-based ASBA process.

When does the issue open and close?

Per the RHP, anchor bidding took place on 28 July 2026, the public issue opened on 29 July 2026, and bidding closes on 31 July 2026, with the UPI mandate cut-off at 5:00 p.m. on the closing day.

What are the objects of the issue?

Per the RHP, the fresh-issue proceeds are earmarked for repaying certain borrowings of subsidiary Manipal Hospitals Private Limited, acquiring a minority stake in Sahyadri Hospitals Private Limited, and general corporate purposes. The company will not receive any proceeds from the offer-for-sale portion.

Where can I read the RHP?

The red herring prospectus is available on SEBI's website and on the BSE and NSE websites, as well as on the company's and the lead managers' websites, as stated in the offer document.

This report is based on the red herring prospectus filed with SEBI and the offer terms disclosed to the exchanges. It was surfaced via coverage on the Mint IPO desk.